< Back to previous page
Researcher
Patrick Schöffski
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Oncology (Division)
Responsible
From1 Jan 2012 → Today - Laboratory of Experimental Oncology (Division)
Member
From1 Oct 2005 → Today
Projects
1 - 10 of 12
- Real-time qPCR platform enhancing research activities within the Laboratory of Experimental Oncology and the Laboratory of Experimental RadiotherapyFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- PhD student in preclinical research on sarcoma treatmentFrom3 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Preclinical evaluation of innovative cytotoxic drugs for the treatment of soft tissue sarcomaFrom28 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Whole-genome optical mapping for comprehensive analysis of sarcoma genomes in a diagnostic settingFrom13 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Exploring the biology of translocation-related sarcomas and impact on the research for new therapy options.From1 Oct 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- CYTOTOXIC THERAPY REVISED: EXPLORATION OF INNOVATIVE (PRO)DRUGS IN PATIENT-DERIVED XENOGRAFTS OF SOFT TISSUE SARCOMAFrom1 Sep 2018 → 25 Oct 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- Molecular characterization of soft tissue sarcoma and the potential clinical applicationsFrom26 Sep 2017 → 25 Feb 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- Clinical outcome, Pathological results and immunohistochemical findings of rare subtypes of soft tissue sarcomasFrom10 Aug 2015 → 30 Sep 2017Funding: Nonprofit institution or equivalents
- Establishment of new research models and in vivo efficacy testing of novel treatment strategies for resistant gastrointestinal stromal tumorsFrom1 Aug 2014 → 19 May 2017Funding: Own budget, for example: patrimony, inscription fees, gifts
- Targeting soft tissue sarcoma with smart molecules - exploring cytotoxic prodrugs and target-specific inhibitors in patient-derived xenograftsFrom1 Aug 2013 → 30 Nov 2017Funding: Nonprofit institution or equivalents
Publications
311 - 320 of 384
- Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours(2011)
Authors: Herlinde Dumez, Benoit Beuselinck, Patrick Schöffski
Pages: 1328 - 1335 - Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study(2011)
Authors: Patrick Schöffski
Pages: 1006 - 1012 - Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma The European Organisation for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study(2011)
Authors: Patrick Schöffski
Pages: 1544 - 1550 - Patient adherence to oral anticancer drugs: an emerging issue in modern oncology(2011)
Authors: Veerle Foulon, Patrick Schöffski
Pages: 85 - 96 - Intrinsic cell memory reinforces myogenic commitment of pericyte-derived iPSCs(2011)
Authors: Mattia Quattrocelli, Giacomo Palazzolo, Beppe Floris, Patrick Schöffski, Thierry Vandendriessche, Marinee Chuah, Catherine Verfaillie, Maurilio Sampaolesi
Pages: 593 - 603 - Papillary serous carcinoma of the peritoneum after risk reducing salpingo-oophorectomy (RRSO) in a woman with BRCA 1 mutation(2011)
Authors: Patrick Schöffski, Hans Wildiers
Pages: 57 - 61 - A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma(2011)
Authors: Patrick Schöffski
Pages: 679 - 686 - Retroperitoneal Dedifferentiated Liposarcomas with Production of β-Human Chorionic Gonadotropin - a Distinct Sarcoma Entity?(2011)
Authors: Patrick Schöffski, Kathleen Forceville, Maria Debiec-Rychter, Agnieszka Wozniak, Raf Sciot
Pages: 122 - 5 - Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer(2011)
Authors: Vincent Vander Poorten, Sandra Nuyts, Esther Hauben, Joseph Schoenaers, Patrick Schöffski, Paul Clement
Pages: 1 - 6 - Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy(2010)
Authors: Patrick Schöffski
Pages: 4906 - 4911